<page><tag>3</tag><title>Maxim Dives 61 Pct on Drug Trial Result</title><text> PHILADELPHIA (Reuters) - Maxim Pharmaceuticals Inc.  &amp;lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=MAXM.O target=/stocks/quickinfo/fullquote"&amp;gt;MAXM.O&amp;lt;/A&amp;gt; said a trial to confirm the benefit of its Ceplene  drug failed to show an improvement in survival rates for  patients with liver cancer, sending its shares plunging on  Monday.</text></page>